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Dabigatran as Alternative Anticoagulant for Intra-Aortic Balloon
Pump in a Patient with Suspected Heparin-Induced Thrombocytopenia
JOE KIN-TONG LEE,1 KIN-LAM TSUI,1 HO-NAM WONG,2 BONNIE CHI-SHAN KHO,2 HERMAN SUNG-YU
LIU,2 KWOK-KEUNG CHAN,1 SHU-KIN LI1
From 1Division of Cardiology; 2Division of Haematology, Department of Medicine, Pamela Youde Nethersole Eastern
Hospital, Hong Kong
LEE ET AL.: Dabigatran as Alternative Anticoagulant for Intra-Aortic Balloon Pump in a Patient with Suspected
Heparin-Induced Thrombocytopenia. Heparin induced thrombocytopenia (HIT) is an uncommon condition but can
result in devastating outcomes. Alternative anticoagulants are recommended for HIT patients with on-going needs of
anticoagulation. We report a case of cardiogenic shock treated with intra-aortic balloon pump. The patient was
complicated with isolated HIT after administration of low-molecular-weight heparin, and was successfully managed
with dabigatran, an oral direct thrombin inhibitor, as an alternative anticoagulant. (J HK Coll Cardiol 2013;21:
15-20)
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Introduction
Two types of heparin-induced thrombocytopenia
(HIT) have been described. Type 1 HIT is a nonimmunogenic form of HIT and occurs more
commonly. It usually occurs within the first 2 days
after heparin administration and platelet counts often
return to normal despite continuation of heparin. The
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immune-mediated (type 2) HIT is of clinical importance.
In the rest of the article, the term HIT refers to immunemediated HIT unless otherwise specified. In susceptible
patients receiving heparin, HIT antibodies are formed
and bind to heparin-platelet factor 4 (PF4) complexes.
Such an interaction triggers platelets activation and
aggregation, and therefore leads to thrombocytopenia
and thrombotic phenomenon in HIT. Patients who are
using unfractionated heparin have an absolute risk
of 2.6% to develop HIT, although the use of lowmolecular-weight heparin may reduce the risk by tenfold.1 Among patients with acute coronary syndrome
using heparin, a similar incidence rate of 1.6% is
reported.2 The occurrence is uncommon but the clinical
consequence can be severe. Therefore heparin, being a
substrate to cause HIT, should be discontinued in these
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patients. However it is frequently compelling to continue
anticoagulation for the initial indications of
heparinization, for examples, in patients requiring
haemodynamic support from intra-aortic balloon pump
(IABP) and extracorporeal membrane oxygenation.
Anticoagulation should also be continued in patients
with HIT, as thrombosis prophylaxis or as treatment of
established thrombosis if any. Different classes of
anticoagulants other than heparin, including direct
thrombin inhibitors (lepirudin, bivalirudin, argatroban),
synthetic pentasaccharide (fondaparinux), and direct
factor-Xa inhibitor (danaparoid) have been shown to
be useful alternatives in such patients who are
contraindicated to heparin.3-8 Unfortunately, these agents
are not readily available in some parts of the world,
including in our locality. We report the use of dabigatran,
an oral direct thrombin inhibitor (DTI), as an alternative
anticoagulant in a patient on IABP who developed
isolated HIT after administration of low-molecularweight heparin. To our knowledge, the clinical evidence
describing the use of dabigatran in patients with HIT is
scarce. Dabigatran may have both advantages and
disadvantages over other anticoagulants in managing
patients with HIT.

Case Report
A 70-year-old man was admitted to the hospital
for anterior ST elevation myocardial infarction, with
the presenting symptom of chest pain. He developed an
episode of witnessed cardiac arrest due to ventricular
fibrillation in the Emergency Department and the
arrhythmia was promptly aborted by external
defibrillation. The patient developed shock with blood
pressure of 77/62 mmHg. He was also intubated and
mechanically ventilated for respiratory failure.
Electrocardiogram showed sinus rhythm and 2 mm
ST segment elevation over the anterior chest leads.
Severe pulmonary congestion was noted on chest
X-ray. The patient was started on dopamine and an IABP
was inserted for haemodynamic support. An urgent
coronary angiogram showed a total thrombotic
occlusion at the left main coronary artery. Primary PCI
was performed, with a drug-eluting stent implanted to
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the left main artery. In view of the high thrombus load,
a bolus dose of intra-coronary eptifibatide was given,
followed by intravenous infusion over the next 24 hours.
The patient was started on double antiplatelet agents,
by loading aspirin 320 mg and clopidogrel 600 mg,
followed by regular doses of aspirin 80 mg daily and
clopidogrel 75 mg daily. He was also started on
intravenous furosemide for diuresis, intravenous
amoxicillin-clavulanate for possible secondary chest
infection, intravenous ranitidine as prophylaxis for stress
peptic ulcer, and subcutaneous tinzaparin 12,000
anti-Xa units every 24 hours (based on the patient's
body weight 63 kg) as anticoagulant for the IABP.
Subsequent blood tests showed a sudden and
remarkable drop of platelet counts, from 166x109/L on
admission, to a trough level of 59x109/L on the fifth
day of hospitalization (Figure 1). The red and white
cell counts, prothrombin time and activated partial
thromboplastin time (aPTT) were unremarkable. His
renal function was normal, with creatinine level of 63
umol/L (estimated creatinine clearance 85.8 mL/min).
Such a late drop of platelet counts was considered
unlikely due to IABP-related thrombocytopenia or the
use of glycoprotein IIb/IIIa inhibitor. Because of the
timing (on day 5 after the administration of lowmolecular-weight heparin) and the degree of drop in
platelet counts (more than 50% drop than baseline level)
with no obvious alternative explanation, a diagnosis of
isolated HIT was suspected. Clinically there was no
overt bleeding, skin necrosis or thromboembolic
event, although doppler ultrasound had not been
performed to detect any clinically silent deep vein
thrombosis. The 4T's score for HIT was 5 (2 points for
thrombocytopenia, 2 points for timing of platelet
count fall, 0 points for thrombosis or other sequelae,
1 point for other causes for thrombocytopenia
present, as the use of IABP and eptifibatide may cause
thrombocytopenia but less likely in this case), indicating
the intermediate probability of HIT.9 Functional assay
for platelet activation, or immunoassay for heparin-PF4
antibodies were not performed as confirmatory tests
because they were not readily available in our hospital.
Therefore tinzaparin was taken off and dabigatran
(PRADAXA , Boehringer Ingelheim, Germany)
110 mg was given every 12 hours via the feeding tube
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as an alternative anticoagulant for the IABP. Clotting
profile was checked 4.5 hours after initiation of
dabigatran and the aPTT prolonged from the baseline
24 seconds to 42 seconds (reference: 24-38 seconds),
which was believed due to the anticoagulation effect
from dabigatran. The aPTT remained prolonged in the

following few days when the patient was still on
dabigatran. The continuous heparin saline flush through
the IABP was also switched to normal saline. The
platelet counts gradually improved and normalized on
the fifty day after putting on dabigatran. The patient
showed clinical improvement and was able to wean off

Ranitidine 50mg q8h iv
Simvastatin 20mg QD po
Clopidogrel 75mg QD po*
Aspirin 80mg QD po†
Amoxicillin/clavulanate 1000/200mg q8h iv
Morphine & midazolam infusion
Furosemide iv
Dabigatran 110mg BD po
Tinzaparin 12,000 anti-Xa units QD sc
Eptifibatide iv‡
Dopamine infusion iv
Intra-aortic balloon pump

*Loading dose 600 mg on Day 1
†Loading dose 320 mg on Day 1
‡Intra-coronary bolus 12 mg during PCI, followed by 8 mg/hr iv infusion
Abbreviation: q8h (every 8 hours); iv (intravenous); QD (daily); po (per oral); BD (twice daily); sc (subcutaneous)
Figure 1. The list of medications administered, in conjoint with the trend of platelet counts in the first 12 days of hospitalization.
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the IABP on day 9. Dabigatran was stopped once the
IABP was taken off. Further anticoagulation was not
contemplated, in view of absence of clinical thrombotic
event and the bleeding risk associated with the
concomitant use of double antiplatelet agents after
implantation of a drug eluting stent. He was wean off
the mechanical ventilation soon afterwards. He made
good progress in rehabilitation and was discharged after
32 days of hospitalization. No clinical thrombotic event
was noted during the disease course and recovery period.

Discussion
Non-heparin anticoagulants, including lepirudin,
bivalirudin, argatroban, fondaparinux, and danaparoid,
are used to treat HIT. However there is not much clinical
evidence describing the use of novel oral anticoagulants
for this indication. Fieland and Taylor have reported
the use of dabigatran for stroke prevention in a patient
with non-valvular atrial fibrillation who developed
thrombocytopenia after coronary artery bypass graft
surgery. The patient was subsequently found to have
heparin-PF4 antibodies.10 However the clinical diagnosis
of HIT in this case was not established, in view of the
absence of thrombotic event, low probability of HIT as
defined by the 4T's score, and the possible confounding
effects on thrombocytopenia and heparin-PF4 antibodies
by cardiopulmonary bypass.11 In our case report, we
describe the use of dabigatran as an alternative
anticoagulation regimen in a patient with clinically
diagnosed isolated HIT and yet required ongoing
anticoagulation for the IABP. We endorsed the 110 mg
twice daily dosage as we took reference from the RELY
trial that this dosage was non-inferior to warfarin for
stroke prevention in patients with non-valvular atrial
fibrillation.12 We avoided the 150mg twice daily dose
in view of the bleeding risk associated with the
concomitant use of double antiplatelet agents. Another
reason to use the 110 mg, instead of 150 mg, twice daily
dose is that administration of crushed dabigatran
pellets without the capsule shell increases the oral
bioavailability by 75%, which can precipitate bleeding
complication.13 For this reason the manufacturer advises
against taking the drug with the capsule broken, chewed
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or opened. We still decided to give crushed dabigatran
pellets via the feeding tube in this patient because we
were left with no treatment option, as those non-heparin
parental anticoagulants were not available in our unit.
Dabigatran has the properties of reversible, rapid
and selective inhibition of thrombin. It is rapidly
absorbed from oral route and once absorbed, the prodrug dabigatran etexilate is converted to the biologically
active form dabigatran. Dabigatran is approved for the
use of stroke prevention in non-valvular atrial
fibrillation, and deep vein thrombosis prophylaxis after
orthopaedic surgery.12,14 We believe that dabigatran,
being an univalent DTI, can act like other parenteral
DTIs to exert an anticoagulation effect, and at the same
time not precipitating or aggravating the pathological
process of HIT. It is supported by the fact that the
molecular structures of dabigatran and other parenteral
DTIs are dissimilar to that of heparin, making the DTI
unlikely to form complexes with PF4 and then to trigger
platelet activation. The parenteral DTIs have not been
shown to cause the pathological processes of HIT.15
Similarly, a recent in-vitro study also demonstrated that
dabigatran does not potentiate the interactions of PF4
or anti-heparin-PF4 antibodies with platelets, supporting
its practical use in patients with acute or history of HIT.16
Compared with other non-heparin anticoagulants
which have established roles in HIT, dabigatran has
several potential advantages: dabigatran has predictable
pharmacokinetic and pharmacodynamic profiles, and at
the same time it provides therapeutic anticoagulation
effect with large safety margin.17 Therefore it can be
taken with a fixed dosage, and blood tests for the purpose
of drug titration is non-essential for approved
indications. The property of reversible binding to
thrombin may also provide a better side effect profile
when compared with other DTIs with irreversible
thrombin binding, such as lepirudin. DTI with reversible
thrombin binding leaves a small amount of free,
enzymatically active thrombin available for control of
haemostasis.17,18 The better risk-benefit ratio is seen in
an experimental model, in which melagatran, also a
reversible thrombin binder, provides a lower bleeding
risk than irreversible thrombin binder hirudin. 19
Nevertheless, an effective antidote of dabigatran has not
yet been established. On-going anticoagulation for
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certain duration is usually required after the initial
thrombocytopenic phase in HIT, and these patients
are usually managed by switching the parental
anticoagulants to warfarin. The use of dabigatran can
omit this medication transition, and at the same time
offering benefit over warfarin by not requiring drug
titration.
For dabigatran being a drug in oral preparation,
the alterations of pharmacokinetics in critically ill
patients may make it less effective. Reduced gut motility
and diminished gastrointestinal tract perfusion due to
blood shunting occur in patients who are critically
ill, in shock or using inotropes. In general, such
physiological responses impede drugs absorption from
the gastrointestinal tract, and therefore lead to a delay
in achieving peak serum concentration, and possibly
lower total drugs exposure, i.e. smaller area under curve
for time and drugs concentration.20 As dabigatran is
administered twice daily, the trough plasma drug level
and therefore its anticoagulation effect are particularly
vulnerable to reach the subtherapeutic range when drug
absorption is impeded. In contrast, such a phenomenon
is less likely to occur in most of the parental
anticoagulants used for HIT treatment, which are
administered by continuous infusion with titration of
dosage according to the clotting profile. Acute kidney
injury is not uncommon in these critically ill patients
and can lead to diminished renal clearance of dabigatran,
which in turn increases the risk of adverse drug effects
such as bleeding. Although there is a lack of study
working specifically on the dabigatran pharmacokinetics
in critically ill patients, we may have some clues from
studies investigated on subjects who have undergone
orthopaedic surgery and have received dabigatran as
prophylaxis for deep vein thrombosis. The postoperative
physiological changes may resemble that of a critically
ill patient to some extent: Lower peak plasma dabigatran
level and a delay in reaching the plasma peak level are
found during the early postoperative period, when
compared with the healthy control subjects.21,22 Such
findings are considered due to reduced gastric motility
and gastric pH following surgery. We had not checked
the plasma dabigatran level or the ecarin clotting time
in our case to confirm adequate drug absorption and
therapeutic anticoagulation effect during the critically
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ill status. Having acknowledged the limitation of nonlinear relationship between aPTT and plasma dabigatran
level, we believe certain anticoagulation effect had been
exerted as suggested by the prolonged aPTT.
Eptifibatide can also cause thrombocytopenia.
The incidence of eptifibatide-induced moderate
thrombocytopenia (<100x109/L) is 3.8%, while severe
thrombocytopenia (<50x109/L) occurs uncommonly,
with an incidence of 0.6%23. In the presented case,
eptifibatide had been used on day 1 and 2, and the
onset of thrombocytopenia was on day 5. The use of
eptifibatide was unlikely the cause of thrombocytopenia,
as glycoprotein IIb/IIIa inhibitors-induced
thrombocytopenia occurs early, typically within 24
hours from the initiation of treatment. The use of IABP
is commonly associated with thrombocytopenia. It
appears that the occurrence of thrombocytopenia is
independent of the use of heparin, but instead the
mechanical force of IABP takes into account.24 IABPrelated thrombocytopenia usually takes place right after
the administration of IABP and the platelet counts drop
gradually to a nadir on day 3 to day 4.24-26 In our reported
patient, the pattern of stable platelet counts initially with
a sudden drop on day 5 was more compatible with HIT
instead of IABP-related thrombocytopenia. Although
the use of beta-lactam antibiotic can also cause
thrombocytopenia, the normalized platelet counts
despite continuation of amoxicillin-clavulanate rejected
the diagnosis of antibiotic-induced thrombocytopenia.
We did not performed any functional or antibodies assay
to ascertain the immune-mediated mechanism of HIT,
as patients having non-immune-mediated HIT (type 1)
usually do well when heparin is continued and need not
to have alternative anticoagulant. Nevertheless, the
molecular dissimilarity of dabigatran with heparin, and
the results of in-vitro molecular studies make dabigatran
a potential option in patients with HIT.15,16 More clinical
studies are required to prove its efficacy and safety in
HIT.

Conclusion
Several alternative anticoagulants have
established their roles in treating patients with HIT, but
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the drug supplies are not always available. The novel
oral DTI dabigatran has structural dissimilarity to
heparin. Its lack of interaction in the pathological
process of HIT make it a feasible option in treating
patients with HIT and a need of ongoing anticoagulation.
Because of its pharmacokinetic and pharmacodynamic
properties, dabigatran has both potential advantages and
disadvantages to the other anticoagulants.
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